Gram-positive bacterial resistance: A challenge for the next millennium

Panminerva Medica

Volumn 44, Issue 3, 2002, Pages 179-184

  Bassetti, M ^a,b   Melica, G ^a   Cenderello, G ^a   Rosso, R ^a   Di Biagio, A ^a   Bassetti, D ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Anti infective agents, administration and dosage; Anti infective agents, adverse effects; Drug resistance, microbial; Gram positive bacterial infections, drug therapy

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; OXAZOLIDINONE DERIVATIVE; QUINUPRISTIN-DALFOPRISTIN; VANCOMYCIN; VIRGINIAMYCIN;

ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HUMAN; PHYSIOLOGY; REVIEW; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ENTEROCOCCUS; GRAM-POSITIVE BACTERIA; HUMANS; OXAZOLIDINONES; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VIRGINIAMYCIN;

EID: 0036715547     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Crowe M, Ispahani P, Humphreys H, Kelley T, Winter R. Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985-1996. Eur J Clin Microbiol Infect Dis 1998;17(6):377-84.
2. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-61.
3. Uttley AHC, George RC, Naidoo J, Woodford N, Johnson AP, Collins CH et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989;103:173-81.
4. Bell JM, Paton JC, Turnidge J. Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates. J Clin Microbiol 1998;36:2187-90.
5. Clark N, Cooksey R, Hill B, Swenson J, Tenover F. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother 1993;37:2311-7.
6. Suppola JP, Kolho E, Salmenlinna S, Tarkka E, Vuopio-Varkila J, Vaara M. vanA and vanB incorporate into an endemic ampicillin-resistant vancomycin-sensitive Enterococcus faecium strain: effect on interpretation of clonality. J Clin Microbiol 1999;37:3934-9.
7. Moellering RC Jr. Emergence of Enterococcus as a significant pathogen. Clin Infect Dis 1992;14:1173-8.
8. Murray BE. Diversity among multidrug-resistant enterococci. Emerg Infect Dis 1998;4:37-47.
9. McCarthy KM, Van Nierop W, Duse A, Von Gottberg A, Kassel M, Perovic O. Control of an outbreak of vancomycin-resistant Enterococcus faecium in an oncology ward in South Africa: effective use of limited resources. J Hosp Infect 2000;44:294-300.
10. Von Gottberg A, Van Nierop W, Duse A, Kassel M, McCarthy K, Brink A. Epidemiology of glycopeptide-resistant enterococci colonizing high-risk patients in hospitals in Johannesburg, Republic of South Africa. J Clin Microbiol 2000;38:905-9.
11. Gambarotto K, Ploy MC, Turlure P, Grelaud C, Martin C, Bordessoule D et al. Prevalence of vancomycin-resistant enterococci in fecal samples from hospitalized patients and non-hospitalized controls in a cattle-rearing area of France. J Clin Microbiol 2000;38:620-4.
12. van den Braak E, van Belkum B, van Keulen F, Vliegenhart J, Verbrugh H. Molecular characterization of vancomicyn resistant enterococci from hospitalized patients and poultry in The Netherlands. J Clin Microbiol 1998;36(7):1927-32.
13. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguzi T, Tenover FC. Methicillin resistant Staphylococcus aureus clinical strain with reduced vancomicyn susceptibility. J Antimicrobial Chemother 1997;40:135-6.
14. Watanabe T. The problems of drug-resistant pathogenic bacteria. The origin of R factors. Ann N Y Acad Sci 1971;182(11):126-40.
15. Watanabe T. Infectious drug resistance in bacteria. Curr Top Microbiol Immunol 1971;56:43-98.
16. Ferraz V, Duse AG, Kassel M, Black AD, Ito T, Hiramatsu K. Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S Afr Med J 2000;90(11):1113.
17. Trakulsomboon S, Danchaivijitr S, Rongrungruang Y, Dhiraputra C, Susaemgrat W, Ito T et al. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J Clin Microbiol 2001;39(2):591-5.
18. Pina P, Marliere C, Vandenesch F, Bedos JP, Etienne J, Allouch PY. An outbreak of Staphylococcus aureus strains with reduced susceptibility to glycopeptides in a French general hospital. Clin Infect Dis 2000;31(5):1306-8.
19. Kim MN, Pai CH, Woo JH, Ryu JS, Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000;38(10):3879-81.
20. Guerin F, Buu-Hoi A, Mainardi JL, Kac G, Colardelle N, Vaupre S et al. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptidesin a Parisian hospital. J Clin Microbiol 2000;38(8):2985-8.
21. Dos Santos Soares MJ, Da Silva-Carvalho MC, Ferreira-Carvalho BT, Figueiredo AM. Spread of methicillin-resistant Staphylococcus aureus belonging to the Brazilian epidemic clone in a general hospital and emergence of heterogenous resistance to glycopeptide antibiotics among these isolates. J Hosp Infect 2000;44(4):301-8.
22. Woodford N, Warner M, Aucken HM. Vancomycin resistance among epidemic strains of methicillin-resistant Staphylococcus aureus in and wales. J Antimicrob Chemother 2000;45(2):258-9.
23. Bierbaum G, Fuchs K, Lenz W, Szekat C, Sahl HG. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Clin Microbiol Infect Dis 1999;18(10):691-6.
24. Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Infect Dis 1999:5(1):147-9.
25. Marchese A, Balistreri G, Tonoli E, Debbia EA, Schito GC. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol 2000;38(2):866-9.
26. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340(7):517-23.
27. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7(2):327-32.
28. Bobin-Dubreux S, Reverdy ME, Nervi C, Rougier M, Bolmstrom A, Vandenesch F et al. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. Antimicrob Agents Chemother 2001;45:349-52
29. von Gottberg A, Ferraz V, Duse AG. Emerging glycopeptide resistance in Gram-positive organisms. S Afr Med J 2000;90(11): 1108-9.
30. Mantero E, Bassetti M, Moroni C, Cenderello G, Bassetti D. Treatment of prosthetic infections sustained by hetero-resistant S. aureus in pediatrics. First International Symposium on resistant Gram-positive infections; 2000 Dec 3-5; San Antonio, Texas, Abs, H4.
31. Perry CM, Jarvis B. Linezolid, a review of its use in the management of serious Gram-positive infections. Drugs 2001;61:525-51.
32. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin resistant E. faecium resistant to linezolid. Lancet 2001;357(9263):1179.
33. Clemett D, Merkhem A. Linezolid. Drugs 2000;59(4):815-27.
34. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44(12):3408-13.
35. Bassetti M, Di Biagio A, Cenderello G, Del Bono V, Palermo A, Cruciani M et al. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). J Infect 2001;43(2):1489.
36. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000;46(5):775-84.
37. Fagon J, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG et al. Treatment of Gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000;161(3 Pt 1):753-62.
38. Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: 2 randomized, multicentre studies of quinupristin/ dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999;44(2):263-73.
39. Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis 1999;18(3):199-202.
40. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections, caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999;44(2):251-61.
41. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999;44:37-46.
42. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000;46:775-84.